| Year |
Citation |
Score |
| 2023 |
Burris TP, de Vera IMS, Cote I, Flaveny CA, Wanninayake US, Chatterjee A, Walker JK, Steinauer N, Zhang J, Coons LA, Korach KS, Cain DW, Hollenberg AN, Webb P, Forrest D, ... ... Griffett K, et al. . Pharmacological Reviews. PMID 37586884 DOI: 10.1124/pharmrev.121.000436 |
0.599 |
|
| 2023 |
Hampton CS, Sitaula S, Billon C, Haynes K, Avdagic A, Wanninayake U, Adeyemi CM, Chatterjee A, Griffett K, Banerjee S, Burris SL, Schoepke E, Boehm T, Bess A, de Vera IMS, et al. Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915. European Journal of Medicinal Chemistry. 258: 115582. PMID 37421886 DOI: 10.1016/j.ejmech.2023.115582 |
0.623 |
|
| 2023 |
Makhija S, Griffett JD, Veerakanellore GB, Burris TP, Elgendy B, Griffett K. REV-ERB activation as a novel pharmacological approach for treating inflammatory pain. Frontiers in Pharmacology. 14: 1171931. PMID 37153791 DOI: 10.3389/fphar.2023.1171931 |
0.481 |
|
| 2023 |
Griffett K, Burris TP. Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases. Frontiers in Medicine. 10: 1102469. PMID 36817797 DOI: 10.3389/fmed.2023.1102469 |
0.596 |
|
| 2022 |
Griffett K, Hayes M, Bedia-Diaz G, Appourchaux K, Sanders R, Boeckman MP, Koelblen T, Zhang J, Schulman IG, Elgendy B, Burris TP. Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists. Acs Chemical Biology. PMID 35417135 DOI: 10.1021/acschembio.2c00057 |
0.565 |
|
| 2022 |
Welch RD, Billon C, Losby M, Bedia-Diaz G, Fang Y, Avdagic A, Elgendy B, Burris TP, Griffett K. Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH. Metabolites. 12. PMID 35323681 DOI: 10.3390/metabo12030238 |
0.667 |
|
| 2022 |
Griffett K, Hayes ME, Boeckman MP, Burris TP. The role of REV-ERB in NASH. Acta Pharmacologica Sinica. PMID 35217816 DOI: 10.1038/s41401-022-00883-w |
0.654 |
|
| 2021 |
Elgendy B, Griffett K, Hegazy L, Di Fruscia P, Sample K, Schoepke E, Kamenecka TM, Burris TP. Synthesis and structure activity relationship of the first class of LXR inverse agonists. Bioorganic Chemistry. 119: 105540. PMID 34902646 DOI: 10.1016/j.bioorg.2021.105540 |
0.648 |
|
| 2021 |
Sengupta M, Abuirqeba S, Kameric A, Cecile-Valfort A, Chatterjee A, Griffett K, Burris TP, Flaveny CA. A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis. Plos One. 16: e0249316. PMID 33770118 DOI: 10.1371/journal.pone.0249316 |
0.534 |
|
| 2020 |
Kuehm LM, Khojandi N, Piening A, Klevorn LE, Geraud SC, McLaughlin NR, Griffett K, Burris TP, Pyles KD, Nelson AM, Preuss ML, Bockerstett KA, Donlin MJ, McCommis KS, DiPaolo RJ, et al. Fructose promotes cytoprotection in melanoma tumors and resistance to immunotherapy. Cancer Immunology Research. PMID 33023966 DOI: 10.1158/2326-6066.CIR-20-0396 |
0.471 |
|
| 2020 |
Griffett K, Bedia-Diaz G, Elgendy B, Burris TP. REV-ERB agonism improves liver pathology in a mouse model of NASH. Plos One. 15: e0236000. PMID 33002003 DOI: 10.1371/journal.pone.0236000 |
0.604 |
|
| 2020 |
Griffett K, Bedia-Diaz G, Hegazy L, de Vera IMS, Wanninayake US, Billon C, Koelblen T, Wilhelm ML, Burris TP. The Orphan Nuclear Receptor TLX Is a Receptor for Synthetic and Natural Retinoids. Cell Chemical Biology. PMID 32763139 DOI: 10.1016/J.Chembiol.2020.07.013 |
0.64 |
|
| 2020 |
Griffett K, Diaz G, Sanders R, Hayes M, Burris TP. Abstract 472: Liver X Receptor Ligands Suppress Intestinal Soat2 and Reduce Cholesterol in Mice Fed a High Cholesterol Diet Circulation Research. 127. DOI: 10.1161/res.127.suppl_1.472 |
0.438 |
|
| 2018 |
Sengupta M, Griffett K, Flaveny CA, Burris TP. Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver Disease. Acs Pharmacology & Translational Science. 1: 50-60. PMID 31696159 DOI: 10.1021/acsptsci.8b00003 |
0.585 |
|
| 2018 |
Goher SS, Griffett K, Hegazy L, Elagawany M, Arief MMH, Avdagic A, Banerjee S, Burris TP, Elgendy B. Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffold. Bioorganic & Medicinal Chemistry Letters. PMID 30587446 DOI: 10.1016/J.Bmcl.2018.12.025 |
0.607 |
|
| 2016 |
Griffett K, Burris TP. Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease. Biochemical and Biophysical Research Communications. PMID 27680310 DOI: 10.1016/J.Bbrc.2016.09.036 |
0.683 |
|
| 2015 |
Flaveny CA, Griffett K, El-Gendy Bel-D, Kazantzis M, Sengupta M, Amelio AL, Chatterjee A, Walker J, Solt LA, Kamenecka TM, Burris TP. Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. Cancer Cell. 28: 42-56. PMID 26120082 DOI: 10.1016/J.Ccell.2015.05.007 |
0.631 |
|
| 2015 |
Griffett K, Welch RD, Flaveny CA, Kolar GR, Neuschwander-Tetri BA, Burris TP. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. Molecular Metabolism. 4: 353-7. PMID 25830098 DOI: 10.1016/J.Molmet.2015.01.009 |
0.6 |
|
| 2014 |
Banerjee S, Wang Y, Solt LA, Griffett K, Kazantzis M, Amador A, El-Gendy BM, Huitron-Resendiz S, Roberts AJ, Shin Y, Kamenecka TM, Burris TP. Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour. Nature Communications. 5: 5759. PMID 25536025 DOI: 10.1038/Ncomms6759 |
0.568 |
|
| 2013 |
Griffett K, Burris TP. The mammalian clock and chronopharmacology. Bioorganic & Medicinal Chemistry Letters. 23: 1929-34. PMID 23481644 DOI: 10.1016/J.Bmcl.2013.02.015 |
0.547 |
|
| 2013 |
Burris TP, Solt LA, Wang Y, Crumbley C, Banerjee S, Griffett K, Lundasen T, Hughes T, Kojetin DJ. Nuclear receptors and their selective pharmacologic modulators. Pharmacological Reviews. 65: 710-78. PMID 23457206 DOI: 10.1124/Pr.112.006833 |
0.649 |
|
| 2013 |
Griffett K, Solt LA, El-Gendy Bel-D, Kamenecka TM, Burris TP. A liver-selective LXR inverse agonist that suppresses hepatic steatosis. Acs Chemical Biology. 8: 559-67. PMID 23237488 DOI: 10.1021/Cb300541G |
0.619 |
|
| Show low-probability matches. |